{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-111170","form_type":"8-K","ticker":"RNAZ","cik":"0001829635","company_name":"Transcode Therapeutics, Inc.","filed_at":"2026-09-28T12:16:10+00:00","discovered_at":"2026-09-28T12:20:38.539143+00:00","generated_at":"2026-10-12T13:31:14.087494+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"TransCode's TTX-MC138 shows 71.4% stable disease in Phase 1a; no dose-limiting toxicities","bullets":["10 of 14 efficacy-evaluable patients (71.4%) achieved stable disease as best overall response by investigator assessment; disease control was 57.1% at Cycle 3 Day 1 and 35.7% at Cycle 6 Day 1.","Durability: 6 of 14 patients progression-free at 3 months, 3 at 6, 9 and 12 months; three efficacy-evaluable patients remain progression-free at one year.","No dose-limiting toxicities at any dose including the highest evaluated 4.8 mg/kg; 98 doses administered as of the September 1, 2026 data cutoff; no treatment discontinuations.","Post-hoc Growth Modulation Index: 6 of 15 evaluable patients (40%) had GMI above 1.3, meaning at least 30% longer progression-free interval than their prior therapy.","Exploratory blood RNA-sequencing showed dose-dependent antitumor immune activation; TransCode is evaluating dose-expansion strategies in selected cancers and molecularly defined populations."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-111170","json":"https://secwatch.observer/filing/0001104659-26-111170.json","markdown":"https://secwatch.observer/filing/0001104659-26-111170.md","text":"https://secwatch.observer/filing/0001104659-26-111170.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829635/000110465926111170/0001104659-26-111170-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829635/000110465926111170/tm2626237d1_8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T13:31:14.087494+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}